80 related articles for article (PubMed ID: 3295619)
1. High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Donhuijsen-Ant R; Planker M; Wendt FC; Büchner T
Onkologie; 1987 Feb; 10(1):11-2. PubMed ID: 3295619
[TBL] [Abstract][Full Text] [Related]
2. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho AD; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
Leukemia; 1990 Sep; 4(9):637-40. PubMed ID: 2395383
[TBL] [Abstract][Full Text] [Related]
3. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
4. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias.
Hiddemann W; Büchner T; Essink M; Koch O; Stenzinger W; van de Loo J
Onkologie; 1988 Feb; 11(1):10-2. PubMed ID: 3283619
[TBL] [Abstract][Full Text] [Related]
6. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
[TBL] [Abstract][Full Text] [Related]
7. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1998 Jul; 12(7):1049-55. PubMed ID: 9665189
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Kern W; Schleyer E; Braess J; Wittmer E; Ohnesorge J; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Ann Hematol; 2001 Jun; 80(6):334-9. PubMed ID: 11475146
[TBL] [Abstract][Full Text] [Related]
9. High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Hiddemann W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Becker K; Balleisen L; Lathan B
Leuk Lymphoma; 1993; 10 Suppl():133-7. PubMed ID: 8481662
[TBL] [Abstract][Full Text] [Related]
10. High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Onkologie; 1986 Jun; 9(3):144-6. PubMed ID: 3528960
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
Liso V; Specchia G; Capalbo S; Pavone V; Iacobazzi A; Iaculli ML; Dione R; Pansini N
Acta Haematol; 1992; 87(1-2):54-7. PubMed ID: 1585771
[TBL] [Abstract][Full Text] [Related]
12. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
[TBL] [Abstract][Full Text] [Related]
13. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
14. Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group.
Hiddemann W; Schmitz N; Pfreundschuh M; Pflüger KH; Ollech-Chwoyka J; Tirier C; Maschmeyer G; Kirchner H; Wagner T; Koch P
Cancer; 1990 Sep; 66(5):838-43. PubMed ID: 2386912
[TBL] [Abstract][Full Text] [Related]
15. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
[TBL] [Abstract][Full Text] [Related]
16. [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
Wakita A; Murase T; Uchida T; Fujiwara Y; Tanaka M; Ohkita T
Gan To Kagaku Ryoho; 1992 May; 19(5):653-7. PubMed ID: 1580638
[TBL] [Abstract][Full Text] [Related]
17. [High dosage ARA-C in combination with mitoxantrone in therapy of acute myeloid leukemia in childhood. Initial results of the AML BFM-85 recurrence study].
Ritter J; Creutzig U; Henze G; Jürgens H; Bode U; Prindull G; Schellong G
Onkologie; 1987 Feb; 10(1):24-7. PubMed ID: 3295622
[TBL] [Abstract][Full Text] [Related]
18. Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results.
Hiddemann W; Aul C; Maschmeyer G; Lathan B; Köppler H; Hoffmann R; Grüneisen T; Donhuijsen-Ant R; Ludwig WD; Balleisen L
Onkologie; 1989 Feb; 12(1):4-6. PubMed ID: 2654790
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.
Rosen PJ; Rankin C; Head DR; Boldt DH; Luthardt FW; Norwood T; Pugh RP; Karanes C; Appelbaum FR
Leuk Res; 2000 Mar; 24(3):183-7. PubMed ID: 10738999
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Kantarjian HM; Walters RL; Keating MJ; Estey EH; O'Brien S; Schachner J; McCredie KB; Freireich EJ
Cancer; 1990 Jan; 65(1):5-8. PubMed ID: 2293869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
